Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

LMB-100 4Cyclophosphamide 3fludarabine 2Plicamycin 2Cisplatin 2talazoparib 1pembrolizumab 1olaparib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1amatuximab 1alvocidib 1aldesleukin 1Surgical Procedures, Operative 1Pentostatin 1Pemetrexed 1Paclitaxel 1Magnetic Resonance Imaging 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Famotidine 1FANG vaccine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dexamethasone 1Depsipeptides 1Cytoreduction Surgical Procedures 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma × amatuximab × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡